|
|
Post by biotec on Apr 24, 2014 17:21:42 GMT -5
No bad news, No good news. Very quiet on the mannkind front. No hit pieces! No great pieces! Nothing.Maybe Ill go to Vages for a little excitement.This is like watching paint dry.
|
|
|
|
Post by BD on Apr 24, 2014 17:33:11 GMT -5
Think of it as an opportunity to get a life  |
|
|
|
Post by novafett on Apr 29, 2014 12:31:37 GMT -5
Yea i've been watching the stock price and news tickers from the sidelines of late and not much going on.
What are the key dates / events coming up?
|
|
|
|
Post by mnkdfan on Apr 30, 2014 9:58:21 GMT -5
just another thought while we wait, I have always thought Sanofi would be the best partner option for MNKD. Perhaps today's news release of Sanofi divesting off their matured drug products to focus on high growth areas will pave the way for MNKD. I know it's just speculation but it's my hunch and topic to kill some time.... (Reuters) - Sanofi SA is looking to sell a portfolio of mature drugs that could fetch between $7 billion and $8 billion, according to people familiar with the matter, yet another example of drugmakers trying to shed non-core assets and focus on high-growth areas. The French pharmaceutical company is working with Evercore Partners Inc and has contacted potential buyers in the past few months, the people said on Tuesday, asking not to be named because the matter is private. www.reuters.com/article/2014/04/30/us-sanofi-sale-iduskbn0df1xf20140430MNKD |
|
|
|
Post by babaoriley on Apr 30, 2014 13:18:50 GMT -5
C'mon, all, admit it, did anyone ever think holding MNKD stock could be this boring? I sure as heck didn't!
|
|
|
|
Post by otherottawaguy on Apr 30, 2014 14:43:16 GMT -5
Try trading in and out of 10k shares for a 2% return each time. Should make it interesting for you if your out and the price keeps rising like it is today. Really interesting...
OOG |
|
|
|
Post by babaoriley on Apr 30, 2014 17:53:52 GMT -5
Not a bad idea, oog, especially if MNKD dominates your portfolio, but I have a few other things to tear my hair out over. I was talking with Spiro today, and we both agreed that the stock price has held up well considering where we are in terms of FDA and partnership - not too many people expecting stuff until June at the earliest (I am expecting to have a good time at the AGM, though).
|
|
|
|
Post by biotec on Apr 30, 2014 17:56:31 GMT -5
I Invest in speculative stocks for the excitement, Yes BD This is my life!! So dont tell me to get one!That was a little under the belt rude BTW. Anyway I love biotech stocks for the excitement, Never know whats going to go down next.And with all the research involved with biotech it gives me a life. Anyway you can count out Pfizer as a partner, With the big EQ going about, I dont believe PFE will be a partner,And the sad thing is PFE wants nothing to do with MNKD not the other way around.
|
|
|
|
Post by BD on Apr 30, 2014 19:39:09 GMT -5
biotec, did you notice the winkie?
I have a lot of personal experience with message board stock obsession, though; these days, I'm a firm believer that if there's nothing going on, there's no reason to post. Except, of course, to be social...
|
|
|
|
Post by spiro on Apr 30, 2014 22:42:58 GMT -5
BD is very wise and since I am a firm believer in posting when nothing is going on, I am going to make some bold predictions now.
75% chance of an FDA Afrezza approval before June 15
75% chance of a partnership before July 1
50% chance of Afrezza being acquired within 2 weeks after FDA approval
25% chance of MNKD being bought within 2 weeks of Afrezza approval
10% chance that I will be in Siberia before August 1
99% chance that I will still be posting when nothing is going on
|
|
|
|
Post by mnkdfan on May 6, 2014 14:08:25 GMT -5
Here we go again with the biotech sector getting hit today…… This waiting game is killing me.... Merck just sold off their consumer over the counter drug product line to Bayer for $14.2B and will be even more flushed with cash. Perhaps they’ll use the cash to work out a deal with MNKD….I hope. Merck does not have an insulin product in it’s portfolio other than the oral Januvia. What do you take the below term “external assets” to mean??? "Merck CEO Kenneth Frazier said in January that he was evaluating options for Merck's consumer and animal health businesses, both units without enough scale to grow quickly. On Tuesday, Merck said it would use the sale proceeds to invest in business areas with the highest growth potential and beef up its drug pipeline with "external assets." finance.yahoo.com/news/bayer-buy-merck-consumer-business-113516027.html |
|
|
|
Post by seanismorris on May 6, 2014 18:34:51 GMT -5
Things are happening behind the scenes unfortunately investors don't have the details. I'm seeing patents going from 'patent pending' to approved in 2014. There was also Mannkinds rep talking at a conference in San Diego on May 2nd on inhaled (peptide) pain meds. I assume there was some Torry Pines data presented, which I'd love to have the details on in the next call. There is also TechnoVax getting funding to develope a flu vaccine, but I don't know if the first iteration will be using the Cricket inhaler from Mannkind. That partnership has been disapointing so far... technovax.com/TechnoVax-Awarded-NIH-Grant-for-UFLU-final-01-08-13.pdfUnfortunately, my expectations are for this investor call is low. I predict no partnership announcement until after approval (another two months). I'd be happy with Technosphere pain data to prevent a stock price decline. |
|
|
|
Post by spiro on May 6, 2014 20:59:56 GMT -5
|
|
|
|
Post by seanismorris on May 6, 2014 22:06:44 GMT -5
Here's a bit of news (I'm not going to pay 75$ for the entire interview...any takers?) If only Mannkind was flushed with cash from a partnership deal...there is so much upside I'm having difficult trading shares. .............................. MannKind Corporation (MNKD) Considers Entering Pain Management Market May 06, 2014 MannKind Corporation (MNKD) COO Hakan Edstrom says his company is “looking closely” at expansion opportunities in the pain management market. “If you get the medication into the bloodstream very quickly, you also have a relief of the pain much, much quicker. There are also nonopioid opportunities, where you may even be able to treat patients for their pain without having the risk of them getting into situations where they are dependent on the drug itself because of the side effects,” Edstrom says. “That’s one area that we are looking into right now, and there are some others that I, unfortunately for proprietary reasons, cannot necessarily speak on at this point in time.” FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE. Edstrom says MannKind is still in the preclinical phase of its pain management research. He says the company has conducted feasibility studies, but not yet moved on to subsequent phases of research. “We have had to manage our resources because AFREZZA has been such a major undertaking for the company,” Edstrom says. “We’ve had to be a little bit more conservative in the investment in other areas until we feel that we have a successful product on the market and a partnership, which is what we’re looking to with AFREZZA.” - See more at: www.twst.com/news/1398-mannkind-corporation-mnkd-considers-entering-pain-management#sthash.52KsWpLi.dpuf |
|
|
|
Post by seanismorris on May 6, 2014 22:37:04 GMT -5
Well...the FDA better get on the Afrezza bandwagon. Mannkind may be the last man standing with regards to inhaled insulin, but the rest of the industry is embracing the idea of DPI (dry powder inhalers). See list below. Mannkind needs to license their technology (or partner). Here's one that looks very uncomfortable to use in comparison with gen2 or the Cricket. m.youtube.com/watch?v=6vdDQc_HVM8Here's another another: m.youtube.com/watch?v=jajf3OUFtEk(Mannkinds inhaler technology is so superior it's not even funny) You have to plug your nose, worry about the powder falling out, and gargle after inhaling the medicine. DPI Devices Acu-Breathe (Respirics) Aerolizer Novartis) AIR (Civitas/Alkermes) Airmax (Teva) Aspirair (Vectura) Axahaler (S.M.B.) Breezhaler (Novartis) Clickhaler (Vectura) Conix Dry (3M) Cricket (Mannkind) Cyclohaler (Teva) Diskhaler (GlaxoSmithKline) Diskus (GlaxoSmithKline) Dreamboat (Mannkind) Easyhaler (Orion) EZ Aer (Aerovance) Flexhaler (AstraZeneca) Genuair (Almirall) Gemini (GSK) Handihaler Boehringer Ingelheim) MicroDose (MicroDose Therapeutx) Next DPI (Chiesi) Novolizer (Meda) Oximax (Mantecorp) Podhaler (Novartis) Pulmojet (sanofi-aventis) Pulvinal (Chiesi) Skyehaler (SKyepharma) Solis (Sandoz/Novartis) Taifun (Akela) Taper Dry (3M) Trivair (Trimel Bipharma) Twincaps/Flowcaps (Hovione) Twisthaler (Schering /Merck) Turbuhaler (AstraZeneca) The list of DPI is from www.greystoneassociates.org/Reports/Drug_Delivery/DPI/Dry_Powder_Inhalation.htm |
|
